Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
← catalyst calendarNCT07284459 · readout ≤ 651 d
Sponsored by Contineum Therapeutics (industry) · CTNM — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
324estimated
Sites
65
Countries
Argentina, Australia, Canada +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-08 | actual | When the study began enrolling |
| Primary completion | May 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Idiopathic Pulmonary Fibrosis
Interventions
- Drug: PIPE-791 Dose A — also filed as PIPE-791
- Drug: PIPE-791 Dose B — also filed as PIPE-791
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFAbsolute change in forced vital capacity (FVC) (mL)
measured From baseline to Week 26
Permalink · CTNM's whole pipeline · Catalyst calendar · Every registered study · What changed